IGF2 increases de novo steroidogenesis in prostate cancer cells

Endocrine-Related Cancer

Volumn 20, Issue 2, 2013, Pages 173-186

  Lubik, Amy A ^a,b   Gunter, Jennifer H ^a   Hollier, Brett G ^a   Ettinger, Susan ^b   Fazli, Ladan ^b   Stylianou, Nataly ^a   Hendy, Stephen C ^b   Adomat, Hans H ^b   Gleave, Martin E ^b   Pollak, Michael ^c   Herington, Adrian ^a   Nelson, Colleen C ^a,b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Androgen receptor; Castrate resistant; IGF2; Prostate cancer; Steroidogenesis

Indexed keywords

5ALPHA PREGNANE 3,20 DIONE; ALDO KETO REDUCTASE FAMILY MEMBER 1C3; ANDROGEN RECEPTOR; ANDROSTENEDIONE; ANDROSTERONE; ANTIBODY; CHOLESTEROL; CYTOCHROME P450 17; CYTOCHROME P450 17A1; ENZYME; MESSENGER RNA; OXIDOREDUCTASE; PREGNAN 3,17 DIOL 20 ONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN HSD17B3; PROTEIN RDH5; REGULATOR PROTEIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; STEROID; STEROID 5ALPHA REDUCTASE 1; STEROID ACUTE REGULATORY PROTEIN; STEROID HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEROIDOGENESIS;

CELL LINE, TUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 2; RNA, MESSENGER; STEROIDS;

EID: 84876776416     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0250     Document Type: Article

References (49)

1. Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V & Folkerd E 2008 Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 26 4563. (doi:10.1200/JCO.2007.15.9749)
2. Attard G, Richards J & de Bono J 2011 Targeting the androgen receptor signaling pathway in metastatic prostate cancer. Clinical Cancer Research 17 1649-1657. (doi:10.1158/1078-0432.CCR-10-0567)
3. Auchus R 2004 The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism 15 432-438.
4. Bhusari S, Yang B, Kueck J, HuangW& Jarrard DF 2011 Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 71 1621-1630. (doi:10.1002/pros.21379)
5. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH & Dell-John J 2009 BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Molecular Cancer Therapeutics 8 3341. (doi:10.1158/1535-7163.MCT-09-0499)
6. Cardillo M, Monti S, Di Silverio F, Gentile V, Sciarra F & Toscano V 2003 Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Research 23 3825-3835.
7. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D & Gleave ME 2005 A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Institute 97 1287-1296.
8. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A & Beebe JS 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clinical Cancer Research 11 2063. (doi:10.1158/1078-0432.CCR-04-1070)
9. Cox M, Gleave M, Zakikhani M, Bell R, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L & Pollak M 2009 Insulin receptor expression by human prostate cancers. Prostate 69 33-40. (doi:10.1002/pros.20852)
10. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S,Wu Y, He X, Powe NR & Feinberg AP 2003 Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 1753. (doi:10.1126/science.1080902)
11. Diaz L, Chuan Y, Lewitt M, Fernandez-Perez L, Carrasco-Rodríguez S, Sanchez-Gomez M & Flores-Morales A 2007 IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor. Molecular Human Reproduction 13 567-576. (doi:10.1093/molehr/gam039)
12. Fottner C, Engelhardt D & Weber M 1998 Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. Journal of Endocrinology 158 409. (doi:10.1677/joe.0.1580409)
13. Gregory C, Johnson R, Jr., Mohler J, French F & Wilson E 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 2892-2898.
14. Gualberto A & Pollak M 2009 Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28 3009-3021. (doi:10.1038/onc.2009.172)
15. Harman SM, Metter EJ, Blackman MR, Landis PK & Carter HB 2000 Serum levels of insulin-like growthfactor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. Journal of Clinical Endocrinology and Metabolism 85 4258-4265. (doi:10.1210/jc.85.11. 4258)
16. Horoszewicz J, Leong S, Chu T, Wajsman Z, Friedman M, Papsidero L, Kim U, Chai L, Kakati S, Arya S et al. 1980 The LNCaP cell line -A new model for studies on human prostatic carcinoma. Progress in Clinical and Biological Research 37 115-132.
17. Huang F, HurlburtW, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM & Carboni JM 2010 Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Research 70 7221. (doi:10.1158/0008-5472.CAN-10- 0391)
18. Kalla Singh S, Moretta D, Almaguel F, Wall NR, De Leon M & De Leon D 2007 Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25 363-372. (doi:10.1080/08977190801886905)
19. Kim J & Coetzee GA 2004 Prostate specific antigen gene regulation by androgen receptor. Journal of Cellular Biochemistry 93 233-241. (doi:10.1002/jcb.20228)
20. Knudsen KE & Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism 21 315-324. (doi:10.1016/j.tem.2010.01.002)
21. l'Allemand D, Penhoat A, Lebrethon M, Ardevol R, Baehr V, Oelkers W & Saez J 1996 Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. Journal of Clinical Endocrinology and Metabolism 81 3892-3897. (doi:10.1210/jc.81.11.3892)
22. Leon C, Locke J, Adomat H, Etinger S, Twiddy A, Neumann R, Nelson C, Guns E & Wasan K 2010 Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70 390-400. (doi:10.1002/pros.21072)
23. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2K[D][D] CT method. Methods 25 402-408. (doi:10.1006/meth.2001.1262)
24. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, GleaveME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407. (doi:10.1158/0008-5472.CAN-07-5997)
25. Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME & Guns EST 2009 Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. Journal of Steroid Biochemistry and Molecular Biology 115 126-136. (doi:10.1016/j.jsbmb.2009.03.011)
26. Lubik A, Gunter J, Hendy SC, Locke JA, Adomat H, Thompson V, Gleave M, Pollak M, Herington A & Nelson C 2011 Insulin directly increases de novo steroidogenesis in prostate cancer cells. Cancer Research 71 5754-5764. (doi:10.1158/0008-5472.CAN-10-2470)
27. Monti S, Di Silverio F, Lanzara S, Varasano P, Martini C, Tosti-Croce C & Sciarra F 1998 Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens. Steroids 63 362-366. (doi:10.1016/S0039-128X(98)00034-8)
28. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL & Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Research 61 6276-6280.
29. Pandini G, Conte E, Medico E, Sciacca L, Vigneri R & Belfiore A 2004 IGF-II binding to insulin receptor isoform A induces a partially different gene expression profile from insulin binding. Annals of the New York Academy of Sciences 1028 450-456. (doi:10.1196/annals.1322.053)
30. Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F, Weidner W & Steger K 2009 Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. International Journal of Oncology 35 87-96. (doi:10.3892/ijo-00000316)
31. Poirier K, Chalas C, Tissier F, Couvert P, Mallet V, Carrié A, Marchio A, Sarli D, Gicquel C & Chaussade S 2003 Loss of parental specific methylation at the IGF2 locus in human hepatocellular carcinoma. Journal of Pathology 201 473-479. (doi:10.1002/path.1477)
32. Pollak M 2008a Insulin, insulin-like growth factors and neoplasia. Best Practice & Research. Clinical Endocrinology & Metabolism 22 625-638. (doi:10.1016/j.beem.2008.08.004)
33. Pollak M 2008b Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology 8 384-392. (doi:10.1016/j.coph.2008.07.004)
34. Rowlands M, Gunnell D, Harris R, Vatten L, Holly J & Martin R 2009 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-Analysis. International Journal of Cancer 124 2416-2429. (doi:10.1002/ijc.24202)
35. Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE & Martin RM 2012 Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes & Control 23 347-354. (doi:10.1007/s10552-011-9883-8)
36. Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR & Berchuck A 2005 High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology 96 355-361. (doi:10.1016/j. ygyno.2004.10.012)
37. Schaffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R & Sturis J 2008 A novel high-Affinity peptide antagonist to the insulin receptor. Biochemical and Biophysical Research Communications 376 380-383. (doi:10.1016/j.bbrc.2008.08.151)
38. So A, Gleave M, Hurtado-Col A & Nelson C 2005 Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology 23 1-9. (doi:10.1007/s00345-004-0473-1)
39. Spicer L & Aad P 2007 Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor. Biology of Reproduction 77 18-27. (doi:10.1095/biolreprod.106.058230)
40. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D & Jacobberger JW 1999 A new human prostate carcinoma cell line, 22Rv1. In Vitro Cellular & Developmental Biology 35 403-409. (doi:10.1007/s11626-999-0115-4)
41. Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning TM, Febbo P & Balk S 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
42. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 62 6606.
43. Titus M, Schell M, Lih F, Tomer K & Mohler J 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657. (doi:10.1158/1078-0432.CCR-05-0525)
44. Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P & Michel M 2006 IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. European Urology 49 286-292. (doi:10.1016/j.eururo.2005.08. 022)
45. Ulanet DB, Ludwig DL, Kahn CR & Hanahan D 2010 Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. PNAS 107 10791. (doi:10.1073/pnas. 0914076107)
46. Van Roozendaal C, Gillis A, Klijn J, Van Ooijen B, Claassen C, Eggermont A, Henzen-Logmans S, Oosterhuis J, Foekens J & Looijenga L 1998 Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Letters 437 107-111. (doi:10.1016/S0014- 5793(98)01211-3)
47. Veldscholte J, Ris-Stalpers C, Kuiper G, Jenster G, Berrevoets C, Claassen E, Van Rooij H, Trapman J, Brinkmann A & Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochemical and Biophysical Research Communications 173 534-540. (doi:10.1016/S0006-291X(05)80067-1)
48. Wang YC, Yu SQ, Wang XH, Han BM, Zhao FJ, Zhu GH, Hong Y & Xia SJ 2011 Differences in phenotype and gene expression of prostate stromal cells from patients of varying ages and their influence on tumour formation by prostate epithelial cells. Asian Journal of Andrology 13 732-741. (doi:10.1038/aja.2011. 11)
49. Wu Y, Chhipa RR, Zhang H & Ip C 2011 The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biology & Therapy 11 902-909. (doi:10.4161/cbt.11.10.15187)